|
|
|
|
|
|
Sponsors and Collaborators: |
Eastern Cooperative Oncology Group National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00075946 |
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which rituximab regimen is more effective in treating indolent non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and comparing them to see how well they work in treating patients with low tumor burden indolent stage III non-Hodgkin's lymphoma or stage IV non-Hodgkin's lymphoma.
Condition | Intervention | Phase |
Lymphoma |
Drug: rituximab |
Phase III |
MedlinePlus related topics: | Cancer Lymphoma |
ChemIDplus related topics: | Rituximab |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Active Control |
Official Title: | Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma |
Estimated Enrollment: | 389 |
Study Start Date: | November 2003 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Arm I: Active Comparator
Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
|
Drug: rituximab
Given IV
|
Arm II: Experimental
Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
|
Drug: rituximab
Given IV
|
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histologic subtype (follicular vs other), age (under 60 vs 60 and over), and the time from diagnosis (less than 1 year vs at least 1 year).
Quality of life is assessed at baseline, 3, 6, 12, 24, 36, 48 months, and within 4 weeks of rituximab failure.
Patients are followed at least annually for 15 years from study entry.
PROJECTED ACCRUAL: A total of 389 patients will be accrued for this study within 45 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed non-Hodgkin's lymphoma, including 1 of the following:
Must meet the following criteria for low tumor burden:
No cytopenias, defined as any of the following:
At least 1 objective measurable disease parameter
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
No uncontrolled active infection
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Show 484 Study Locations |
Eastern Cooperative Oncology Group |
National Cancer Institute (NCI) |
Study Chair: | Brad S. Kahl, MD | University of Wisconsin, Madison |
Investigator: | Michael E. Williams, MD | University of Virginia |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Kahl BS, Williams ME, Hong F, et al.: Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: rituximab extended schedule or re-treatment trial (RESORT) . [Abstract] Blood 110 (11): A-3420, 2007.
  |
Study ID Numbers: | CDR0000346359, ECOG-E4402 |
First Received: | January 12, 2004 |
Last Updated: | October 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00075946 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|